212 related articles for article (PubMed ID: 30531478)
1. Assessment of the Abuse Potential of Cebranopadol in Nondependent Recreational Opioid Users: A Phase 1 Randomized Controlled Study.
Göhler K; Sokolowska M; Schoedel KA; Nemeth R; Kleideiter E; Szeto I; Eerdekens MH
J Clin Psychopharmacol; 2019; 39(1):46-56. PubMed ID: 30531478
[TBL] [Abstract][Full Text] [Related]
2. Cebranopadol: A Novel, First-in-Class, Strong Analgesic: Results from a Randomized Phase IIa Clinical Trial in Postoperative Acute Pain.
Scholz A; Bothmer J; Kok M; Hoschen K; Daniels S
Pain Physician; 2018 May; 21(3):E193-E206. PubMed ID: 29871387
[TBL] [Abstract][Full Text] [Related]
3. Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist.
Linz K; Christoph T; Tzschentke TM; Koch T; Schiene K; Gautrois M; Schröder W; Kögel BY; Beier H; Englberger W; Schunk S; De Vry J; Jahnel U; Frosch S
J Pharmacol Exp Ther; 2014 Jun; 349(3):535-48. PubMed ID: 24713140
[TBL] [Abstract][Full Text] [Related]
4. Opioid-type Respiratory Depressant Side Effects of Cebranopadol in Rats Are Limited by Its Nociceptin/Orphanin FQ Peptide Receptor Agonist Activity.
Linz K; Schröder W; Frosch S; Christoph T
Anesthesiology; 2017 Apr; 126(4):708-715. PubMed ID: 28291086
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone.
Shram MJ; Sathyan G; Khanna S; Tudor IC; Nath R; Thipphawong J; Sellers EM
J Clin Psychopharmacol; 2010 Feb; 30(1):25-33. PubMed ID: 20075644
[TBL] [Abstract][Full Text] [Related]
6. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.
Setnik B; Schoedel K; Bartlett C; Dick C; Hakim N; Geoffroy P
J Opioid Manag; 2017; 13(6):449-464. PubMed ID: 29308591
[TBL] [Abstract][Full Text] [Related]
7. Antihyperalgesic, Antiallodynic, and Antinociceptive Effects of Cebranopadol, a Novel Potent Nociceptin/Orphanin FQ and Opioid Receptor Agonist, after Peripheral and Central Administration in Rodent Models of Neuropathic Pain.
Tzschentke TM; Linz K; Frosch S; Christoph T
Pain Pract; 2017 Nov; 17(8):1032-1041. PubMed ID: 28112482
[TBL] [Abstract][Full Text] [Related]
8. Cebranopadol : a first-in-class potent analgesic agent with agonistic activity at nociceptin/orphanin FQ and opioid receptors.
Sałat K; Jakubowska A; Kulig K
Expert Opin Investig Drugs; 2015 Jun; 24(6):837-44. PubMed ID: 25865744
[TBL] [Abstract][Full Text] [Related]
9. Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users.
Setnik B; Bramson C; Bass A; Levy-Cooperman N; Malhotra B; Matschke K; Sommerville KW; Wolfram G; Geoffroy P
J Clin Pharmacol; 2015 Dec; 55(12):1351-61. PubMed ID: 26011742
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Abuse Potential of Asalhydromorphone, a Novel Prodrug of Hydromorphone, After Intranasal Administration in Recreational Drug Users.
Guenther S; Mickle TC; Barrett AC; Smith A; Braeckman R; Kelsh D; Vince B
Pain Med; 2020 Mar; 21(3):511-520. PubMed ID: 30986302
[TBL] [Abstract][Full Text] [Related]
11. Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta™) tablets in nondependent recreational opioid users.
Schoedel KA; Rolleri RL; Faulknor JY; Pixton GC; Chen N; Bass A; Sommerville KW; Sellers E
J Opioid Manag; 2012; 8(5):315-27. PubMed ID: 23247908
[TBL] [Abstract][Full Text] [Related]
12. Nociceptin/orphanin FQ opioid peptide (NOP) receptor and µ-opioid peptide (MOP) receptors both contribute to the anti-hypersensitive effect of cebranopadol in a rat model of arthritic pain.
Schiene K; Schröder W; Linz K; Frosch S; Tzschentke TM; Jansen U; Christoph T
Eur J Pharmacol; 2018 Aug; 832():90-95. PubMed ID: 29753041
[TBL] [Abstract][Full Text] [Related]
13. Human Abuse Potential of Oral NKTR-181 in Recreational Opioid Users: A Randomized, Double-Blind, Crossover Study.
Ge X; Henningfield JE; Siddhanti S; Jobes J; Lu L; Xie S; Ziola M; Kelsh D; Vince B; Di Fonzo CJ; Tagliaferri M; Zalevsky J; Doberstein SK; Hoch U; Eldon MA
Pain Med; 2020 Feb; 21(2):e114-e126. PubMed ID: 31553457
[TBL] [Abstract][Full Text] [Related]
14. Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users.
Backonja M; Webster LR; Setnik B; Bass A; Sommerville KW; Matschke K; Malhotra BK; Wolfram G
Am J Drug Alcohol Abuse; 2016 Sep; 42(5):539-549. PubMed ID: 27211522
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.
Bond M; Schoedel KA; Rabinovich-Guilatt L; Gasior M; Tracewell W; Malamut R; Ma Y; Webster LR
Pain Med; 2018 Aug; 19(8):1597-1612. PubMed ID: 29016880
[TBL] [Abstract][Full Text] [Related]
16. Abuse deterrence testing: A dose ratio escalation study examining naloxone coadministered with intravenous hydromorphone in non-treatment-seeking, opioid-dependent drug users.
Levy-Cooperman N; Schoedel KA; Reiz JL; Thompson D; Chakaraborty B; Geoffroy P; Michalko KJ
J Opioid Manag; 2016; 12(3):165-80. PubMed ID: 27435437
[TBL] [Abstract][Full Text] [Related]
17. Cancer-related chronic pain: Investigation of the novel analgesic drug candidate cebranopadol in a randomized, double-blind, noninferiority trial.
Eerdekens MH; Kapanadze S; Koch ED; Kralidis G; Volkers G; Ahmedzai SH; Meissner W
Eur J Pain; 2019 Mar; 23(3):577-588. PubMed ID: 30365202
[TBL] [Abstract][Full Text] [Related]
18. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial.
Schoedel KA; Szeto I; Setnik B; Sellers EM; Levy-Cooperman N; Mills C; Etges T; Sommerville K
Epilepsy Behav; 2018 Nov; 88():162-171. PubMed ID: 30286443
[TBL] [Abstract][Full Text] [Related]
19. Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recreational opioid users.
Setnik B; Sommerville K; Goli V; Han L; Webster L
Pain Med; 2013 Aug; 14(8):1173-86. PubMed ID: 23745947
[TBL] [Abstract][Full Text] [Related]
20. Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial.
Christoph A; Eerdekens MH; Kok M; Volkers G; Freynhagen R
Pain; 2017 Sep; 158(9):1813-1824. PubMed ID: 28644196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
